Shire

Showing 15 posts of 170 posts found.

Michael Cola resigns from Shire

April 3, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Michael Cola, Shire

Michael Cola has resigned as the president of Shire Specialty Pharmaceuticals after seven years at the firm.  “On behalf of …

Shire image

Shire signs CNS disorders deal with Heptares

March 23, 2012
Research and Development A2A, CNS, GPCR, Heptares, Shire

Shire is to develop and commercialise a novel adenosine A2A antagonist discovered by Heptares currently in pre-clinical development.UK-based Heptares discovers and …

Rare Disease Day

‘Rare Disease Day’ highlights need for research

February 29, 2012
Research and Development, Sales and Marketing Genzyme, Rare Disease Day, Shire

 Today has been designated as Rare Disease Day around the world, with researchers, regulators and the industry all raising awareness …

Shire image

Shire signs antibody research deal with arGEN-X

February 29, 2012
Research and Development Shire, arGEN-X, monoclonal antibodies

Shire has signed a deal with antibody specialists arGEN-X to develop drugs for rare genetic diseases.Rotterdam-based arGEN-X will use its …

Shire image

Shire’s Vpriv plant wins EU approval

February 28, 2012
Manufacturing and Production EMA, Shire, Vpriv

Shire has been told by the European Medicines Agency that it can make use of a manufacturing facility in Lexington, …

Shire picture

Robust sales for Shire

February 13, 2012
Sales and Marketing Replagal, Shire, Vpriv, Vyvanse

A rise in the use of attention deficit and hyperactivity disorder drugs has helped push Shire’s turnover past $4 billion …

Shire signs strategic partnership deal with ICON

January 10, 2012
Research and Development ICON, Shire

Contract research organisation ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to be the sole global provider of …

Shire facility could answer rare disease drug shortage

November 27, 2011
Manufacturing and Production Fabry disease, Gaucher, Shire, Vpriv

Shire has filed applications with the European and US regulators to produce its Gaucher disease drug Vpriv (velaglucerase alfa) at …

Shire’s Firazyr gains US approval after initial setback

September 1, 2011
Sales and Marketing FDA, Firazyr, Shire

After three years of waiting Shire’s Firazyr has been approved by the FDA for sudden attacks of swelling. The US …

Shire sales rocket with 25% growth

July 29, 2011
Sales and Marketing ADHD, Fabry disease, Gaucher's disease, Shire

Specialist pharma company Shire has posted exceptionally strong results for the second quarter, increasing its product sales by 30% and …

Shire gets green light for second Replagal facility

June 28, 2011
Manufacturing and Production Replagal, Shire, Vpriv, pharma manufacturing news

The European Medicines Agency has approved a second manufacturing facility in the USA for Shire’s Fabry disease treatment Replagal. Shire’s …

Shire promotional magnet attracts FDA wrath

May 20, 2011
Medical Communications, Sales and Marketing FDA, Shire

The use of a promotional magnet by marketers at Shire has attracted trouble from the FDA. The magnet, which is …

Shire UK

Shire makes $750m regenerative medicines acquisition

May 18, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Shire, regenerative medicine

Shire’s ambitions to build a regenerative medicine business will soon be realised following its $750 million acquisition of Advanced BioHealing. …

Shire thrives on specialist portfolio

February 11, 2011
Sales and Marketing 2010 pharma results, ADHD, Shire, Vyvanse

Speciality pharma company Shire has posted sales growth of 16%, led by its ADHD treatment Vyvanse. Sales of Vyvanse rose …

Shire bags senior research execs from GSK and Abbott

February 9, 2011
Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development

Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …

The Gateway to Local Adoption Series

Latest content